Back

Propionylpromazine: Unveiling a Novel Inhibitory Agent Against Mycobacterium tuberculosis

Suresh, U.; Punnam, M.; Kartick, C.; Sugunan, P. A.

2024-04-16 microbiology
10.1101/2024.04.16.589721 bioRxiv
Show abstract

The emergence of multidrug-resistant mycobacterium tuberculosis presents a significant hurdle, as it shows resistance to existing standard therapies, underscoring the critical need for novel antibacterial agents. This study presents propionylpromazine as a promising compound with potent activity against M. tuberculosis. Our research indicates that propionylproma zine effectively curtails the proliferation of M. tuberculosis H37Rv. Importantly, propionylpromazine has shown the capability to impede the growth of M. tuberculosis within macrophages without causing detrimental effects. These findings endorse the potential of propionylpromazine to be further developed as a clinical drug for the effective treatment of M. tuberculosis infections.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.